Ulugbek B Nurmatov1, Edmund Rhatigan2, F Estelle R Simons3, Aziz Sheikh4. 1. Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom. Electronic address: Ulugbek.Nurmatov@ed.ac.uk. 2. Victoria Hospital, NHS Fife, Kirkcaldy, United Kingdom. 3. Departments of Pediatrics, Child Health and Immunology, University of Manitoba, Winnipeg, Manitoba, Canada. 4. Allergy & Respiratory Research Group, Centre for Population Health Sciences, The University of Edinburgh, Edinburgh, United Kingdom; Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital/Harvard Medical School, Boston, Massachusetts.
Abstract
BACKGROUND: Anaphylaxis is a serious allergic or hypersensitivity reaction, which is rapid in onset and sometimes can prove fatal. Although H2-antihistamines are often administered for emergency treatment in anaphylaxis, there is uncertainty about their effectiveness in this disease. OBJECTIVE: To assess the benefits and harms of H2-antihistamines in the treatment of anaphylaxis. METHODS: A systematic review was performed of randomized controlled trials and quasi-randomized controlled trials comparing H2-antihistamines with placebo or no intervention in patients with anaphylaxis. RESULTS: The authors failed to identify any eligible studies for inclusion in this systematic review. CONCLUSION: When H2-antihistamines are recommended for anaphylaxis treatment, the status of the evidence base supporting their use should be described. Well-designed randomized controlled trials investigating the role of H2-antihistamines in anaphylaxis treatment are urgently needed.
BACKGROUND: Anaphylaxis is a serious allergic or hypersensitivity reaction, which is rapid in onset and sometimes can prove fatal. Although H2-antihistamines are often administered for emergency treatment in anaphylaxis, there is uncertainty about their effectiveness in this disease. OBJECTIVE: To assess the benefits and harms of H2-antihistamines in the treatment of anaphylaxis. METHODS: A systematic review was performed of randomized controlled trials and quasi-randomized controlled trials comparing H2-antihistamines with placebo or no intervention in patients with anaphylaxis. RESULTS: The authors failed to identify any eligible studies for inclusion in this systematic review. CONCLUSION: When H2-antihistamines are recommended for anaphylaxis treatment, the status of the evidence base supporting their use should be described. Well-designed randomized controlled trials investigating the role of H2-antihistamines in anaphylaxis treatment are urgently needed.
Authors: Andrew F Whyte; Jasmeet Soar; Amy Dodd; Anna Hughes; Nicholas Sargant; Paul J Turner Journal: Clin Med (Lond) Date: 2022-07 Impact factor: 5.410
Authors: Amy Dodd; Anna Hughes; Nicholas Sargant; Andrew F Whyte; Jasmeet Soar; Paul J Turner Journal: Resuscitation Date: 2021-04-23 Impact factor: 5.262
Authors: F Estelle R Simons; Ledit Rf Ardusso; M Beatrice Bilò; Victoria Cardona; Motohiro Ebisawa; Yehia M El-Gamal; Phil Lieberman; Richard F Lockey; Antonella Muraro; Graham Roberts; Mario Sanchez-Borges; Aziz Sheikh; Lynette P Shek; Dana V Wallace; Margitta Worm Journal: World Allergy Organ J Date: 2014-05-30 Impact factor: 4.084
Authors: Carsten Lott; Anatolij Truhlář; Anette Alfonzo; Alessandro Barelli; Violeta González-Salvado; Jochen Hinkelbein; Jerry P Nolan; Peter Paal; Gavin D Perkins; Karl-Christian Thies; Joyce Yeung; David A Zideman; Jasmeet Soar Journal: Notf Rett Med Date: 2021-06-10 Impact factor: 0.826
Authors: F Estelle R Simons; Motohiro Ebisawa; Mario Sanchez-Borges; Bernard Y Thong; Margitta Worm; Luciana Kase Tanno; Richard F Lockey; Yehia M El-Gamal; Simon Ga Brown; Hae-Sim Park; Aziz Sheikh Journal: World Allergy Organ J Date: 2015-10-28 Impact factor: 4.084
Authors: Won Seok Lee; Jaewoo An; Young-Ho Jung; Hye Mi Jee; Kyu-Young Chae; Young A Park; Man Yong Han; Kyung Suk Lee Journal: Biomed Res Int Date: 2020-02-27 Impact factor: 3.411